Thyroid Cancer Post-Op Risk Stratification

How to use: Enter the key features from the surgical pathology report. The calculator applies the ATA 2025 Management Guidelines for Differentiated Thyroid Cancer to assign an initial post-operative risk tier, generate a radioactive iodine recommendation, and outline surveillance targets.

The 2025 ATA guidelines introduced a four-tier system (Low · Low-Intermediate · Intermediate-High · High) replacing the prior 3-tier model. Papillary, Follicular, and Oncocytic cancers are now risk-stratified separately. Applies to Differentiated Thyroid Cancer (DTC) only — does not apply to medullary, anaplastic, or poorly differentiated carcinoma.

1

Histologic Type

Select the primary diagnosis from the pathology report

Papillary Thyroid Carcinoma (PTC) — classical or follicular variantIncludes invasive encapsulated follicular variant (IEFV-PTC)

NIFTP — Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear FeaturesNon-invasive, encapsulated; very low recurrence risk — behaves like benign disease

PTC — aggressive variantTall cell, hobnail, columnar cell, solid/trabecular, diffuse sclerosing, or widely invasive PTC

Follicular Thyroid Carcinoma (FTC)Encapsulated follicular carcinoma; vascular invasion is the primary risk driver (see Step 2)

Oncocytic (Hürthle Cell) Thyroid CarcinomaNow classified separately in ATA 2025; more RAI-resistant and higher baseline recurrence risk

2

Tumor Extent & Resection

Based on surgical and pathology findings

Extra-thyroidal Extension (ETE)

None — tumor confined to thyroid capsule

Microscopic ETE (pETE / T3b) Perithyroidal soft tissue invasion detected on histology only — now classified as lower risk in ATA 2025

Macroscopic ETE — strap muscle invasion only (T4a) Gross invasion of sternohyoid, sternothyroid, or omohyoid muscles

Macroscopic ETE — major structure invasion (T4a/b) Invasion of trachea, larynx, esophagus, recurrent laryngeal nerve, or prevertebral fascia

Completeness of Resection & Margin Status

R0 — Complete resection, all gross disease removed, negative margins

R1 — Positive posterior margin Microscopically positive margin at posterior capsule — higher risk per ATA 2025

R1 — Positive anterior or lateral margin Microscopically positive at non-posterior margin

R2 — Gross residual disease / macroscopic incomplete resection

Vascular InvasionCritical for FTC/Oncocytic; 4-vessel cutoff is the key threshold in ATA 2025

None

Minor vascular invasion 1–3 vessels invaded

Extensive vascular invasion ≥4 vessels invaded — high-risk threshold for FTC and Oncocytic per ATA 2025

Tumor Size

Microcarcinoma — ≤1 cm

1–2 cm

2–4 cm

>4 cm

MultifocalityATA 2025: multifocal disease (even T1) increases recurrence risk — previously only noted for microcarcinoma with ETE

Unifocal

Multifocal Two or more distinct tumor foci

3

Lymph Node Status

ATA 2025 now explicitly distinguishes N1a (central) from N1b (lateral) — N1b carries higher risk

N0 — No lymph node metastases

N1a — Central compartment micrometastases ≤5 nodes, all <0.2 cm, no extranodal extension

N1a — Central compartment, small volume >5 involved central nodes, or nodes 0.2–3 cm

N1b — Lateral compartment nodes present Any lateral (level II–V) nodal disease <3 cm without extranodal extension

N1 — Any node ≥3 cm, or gross extranodal extension Applies to central or lateral nodes

4

Distant Metastases (M Stage)

M0 — No distant metastases

M1 — Distant metastases present Lung, bone, brain, liver, or other distant sites

ATA 2025 — Four-Tier Risk Reference

Key change from ATA 2015: intermediate risk is now split into Low-Intermediate and Intermediate-High. Follicular and Oncocytic cancers are evaluated separately.

✅ Low Risk — recurrence <10%

Intrathyroidal PTC (classical, follicular variant, EFV-PTC); complete resection (R0); N0 or ≤5 central micrometastatic nodes (<0.2 cm)
NIFTP (non-invasive follicular neoplasm with papillary-like nuclei) — very low risk
Intrathyroidal papillary microcarcinoma, unifocal, no ETE, no vascular invasion
FTC with minimal capsular invasion and no vascular invasion
No aggressive histology; no ETE; no distant metastases

🟡 Low-Intermediate Risk — recurrence 10–15%

Microscopic ETE (pETE, T3b) — downgraded from Intermediate in ATA 2015
Minor vascular invasion in PTC or FTC (1–3 vessels)
Multifocal disease (any T1 multifocal — newly incorporated in ATA 2025)
N1a central nodes, small volume (>5 nodes but all <3 cm)
FTC with limited capsular invasion and <4 vessel invasion
Oncocytic carcinoma with minimal invasion (no extensive vascular invasion)
Tumor >4 cm confined to thyroid without other adverse features
Additive rule: Two or more low-intermediate features → reclassify as Intermediate-High

🟠 Intermediate-High Risk — recurrence 16–30%

Aggressive histologic variant (tall cell, hobnail, columnar cell, diffuse sclerosing, solid/trabecular)
Macroscopic ETE into strap muscles only (T4a, limited)
R1 resection — microscopically positive margins (especially posterior margin)
N1b disease — lateral compartment lymph node metastases
N1a with >5 nodes, moderately enlarged central nodes
Two or more low-intermediate risk features coexisting (additive effect)

🔴 High Risk — recurrence >30%

Macroscopic ETE into major structures: trachea, larynx, esophagus, recurrent laryngeal nerve (T4b)
Gross residual disease (R2)
Distant metastases (M1) — lung, bone, brain, liver
Any lymph node ≥3 cm, or gross extranodal extension
FTC or Oncocytic carcinoma with extensive vascular invasion (≥4 vessels)
Widely invasive FTC

RAI Activity Guide (ATA 2025)

The 2025 guidelines emphasize that a large cohort of low-risk patients can safely forgo RAI. Oncocytic cancers have reduced RAI avidity and require individualized discussion.

Risk Tier	RAI Indication	Typical Activity	Goal
Low Risk	Not recommended. Lobectomy alone may be sufficient for many low-risk cases.	Not routinely given	Active surveillance with Tg + US
Low-Intermediate	Selective — discuss individually. May be offered to facilitate Tg monitoring or when micro ETE is present.	30–50 mCi (1.1–1.85 GBq) if given	Remnant ablation to aid surveillance
Intermediate-High	Generally recommended; individualize based on specific features and extent.	50–150 mCi (1.85–5.55 GBq)	Remnant ablation ± adjuvant treatment
High Risk	Strongly recommended. Dosimetry preferred for M1 disease.	100–200 mCi (3.7–7.4 GBq); dosimetry-guided for M1	Adjuvant treatment ± treatment of known disease
Oncocytic (any tier)	Reduced RAI avidity; discuss RAI benefit vs. risk individually even in higher-risk tiers.	Individualized	May be RAI-refractory; consider targeted therapy early

Dynamic Risk Stratification — Response to Therapy

After initial therapy (surgery ± RAI), risk is reassigned dynamically at 6–12 months based on imaging and biochemistry. This response-to-therapy category guides ongoing surveillance intensity.

Response Category	Definition	Estimated Residual Risk
Excellent	No clinical, biochemical, or structural evidence of disease. Suppressed Tg <0.2 ng/mL (or stimulated Tg <1 ng/mL), negative TgAb, negative imaging.	1–4% recurrence
Biochemical Incomplete	Elevated Tg or rising TgAb without structural disease on imaging.	~30% develop structural disease; <1% disease-specific mortality
Structural Incomplete	Persistent or newly identified locoregional or distant structural disease regardless of Tg.	50–85% disease-specific mortality (site-dependent)
Indeterminate	Nonspecific biochemical or structural findings — low-level Tg, nonspecific imaging abnormalities, stable TgAb.	~15–20% will have structural disease on follow-up

TSH Suppression Targets (ATA 2025)

Risk / Response	TSH Target	Duration
High / Intermediate-High (initial)	<0.1 mU/L	Indefinitely while structurally disease-free; reassess annually
Low-Intermediate (initial)	0.1–0.5 mU/L	3–5 years; liberalize with excellent response
Low risk / Excellent response	0.5–2.0 mU/L (low-normal)	May allow normal TSH after 5 years if Tg undetectable
Structural incomplete response (any tier)	<0.1 mU/L	Continue suppression while active disease present
Lobectomy only (low-risk)	0.5–2.0 mU/L	May not require suppression; individualize